Last updated: May 4, 2026
What is ULTRAVIST 370 in regulated terms?
ULTRAVIST 370 is a non-ionic, iodinated contrast medium for diagnostic imaging. It is marketed in multiple geographies under the brand name ULTRAVIST and is positioned for CT and related radiographic procedures that require high iodine concentration.
Core product positioning (label-based):
- Formulation class: non-ionic iodinated contrast
- Iodine concentration: 370 mg iodine/mL (commonly specified as “370”)
- Intended use: intravascular and other imaging indications depending on local labeling (CT, angiography, other radiography use cases vary by jurisdiction)
What is the current clinical trial landscape for ULTRAVIST 370?
No sufficiently complete, drug-specific public trial dataset for ULTRAVIST 370 can be produced from the available evidence in the citation set provided in this response. A complete update requires trial-by-trial confirmation across registries for:
- product identity (ULTRAVIST 370 versus ULTRAVIST variants with different iodine concentration),
- formulation equivalence (same active concentration, osmolality, and salt form),
- recruitment status and endpoints,
- country coverage and protocol design.
Because this response must be complete and accurate, and because trial-level confirmation is not available here, a trial-by-trial update is not provided.
How does ULTRAVIST 370 compete in the contrast media market?
Market structure
The iodinated contrast media market is dominated by branded incumbents and large global portfolios, with product competition driven by:
- reported safety profile in routine use and higher-risk populations,
- viscosity and injection performance at given iodine concentration,
- image quality claims and workflow attributes,
- availability of institution contracts and reimbursement dynamics,
- portfolio breadth across iodine concentrations and use cases.
Competitive set (by class, typical buyers)
Purchasers compare ULTRAVIST 370 against other non-ionic iodinated agents at similar iodine concentrations used for CT and angiography. In practice, procurement decisions are shaped more by formulary access and tender economics than by marginal clinical differences in routine imaging.
What is the market outlook for ULTRAVIST 370?
A quantitative market projection for ULTRAVIST 370 specifically cannot be produced from the available evidence in this response. Reliable projection requires:
- validated country and share splits by brand and iodine concentration,
- documented uptake trends driven by guideline changes and radiology volume,
- penetration by setting (hospital vs imaging centers),
- pricing and tender effects by geography.
Because those brand-specific, concentration-specific inputs are not available here in a traceable form, no numeric forecast is provided.
What R&D and regulatory signals matter for ULTRAVIST 370?
Signal types that typically move valuation
- New head-to-head or non-inferiority studies that can expand label language (e.g., pediatric subpopulations, renal impairment protocols, specific imaging modalities).
- Safety meta-analyses or registry evidence that can shift guideline language for high-risk imaging workflows.
- Manufacturing or supply chain approvals (site changes, updated manufacturing controls) that can affect continuity of supply and tender eligibility.
Signal types that do not create new exclusivity
For contrast media, many “new studies” do not generate meaningful market exclusivity expansion if they do not introduce patentable compositions, processes, or method-of-use claims. Competitive impact usually comes from label differentiation, pricing, and tender coverage rather than long-horizon patent-driven exclusivity.
Business implications (what procurement and investment teams typically do)
Commercial levers
- Secure and defend formulary placement in large hospital groups that run high CT volumes.
- Align supply contracts to volume commitments during tender cycles.
- Optimize product availability and injection-support ecosystem (where offered) to reduce workflow friction.
Risk levers
- Price compression from competitive tenders and private-label dynamics in some markets.
- Substitution effects where comparable non-ionic iodinated agents win based on tender economics.
- Batch supply constraints that can cause lost tender positions even when clinical profiles are similar.
Key Takeaways
- ULTRAVIST 370 is a non-ionic iodinated contrast medium with 370 mg iodine/mL concentration, used for diagnostic imaging.
- A complete clinical trials update for ULTRAVIST 370 (trial list, status, endpoints, and readouts) is not provided because a complete, drug-specific public dataset cannot be verified within the cited evidence set.
- A quantitative market analysis and numeric projection specific to ULTRAVIST 370 is not provided because brand- and concentration-specific input data is not supported in the cited evidence set.
- Commercial outcomes are typically driven by formulary access, tender pricing, and supply continuity rather than patent exclusivity.
FAQs
-
Is ULTRAVIST 370 the same product as other ULTRAVIST iodine concentrations?
No. “370” specifies iodine concentration; other ULTRAVIST strengths can differ in formulation parameters that affect labeling and interchangeability.
-
What endpoints matter most in contrast media clinical studies?
Safety (adverse reactions, hypersensitivity signals) and imaging performance are typically the key endpoints, alongside renal impairment sub-analyses depending on label evolution.
-
What drives ULTRAVIST 370 procurement in hospitals?
Tender contracts, formulary status, price per procedure, delivery reliability, and workflow fit with injection protocols.
-
Do new studies create meaningful exclusivity for contrast agents?
Often they do not. Label expansions and improved positioning can matter, but exclusivity depends on patentable composition, process, or method-of-use claims.
-
What would a credible market projection for ULTRAVIST 370 require?
Brand-level and concentration-level shares by geography, procedure volume forecasts for CT/angiography settings, and pricing/tender discount assumptions.
References
[1] Drugs.com. ULTRAVIST 370 (injection) information. https://www.drugs.com/ (accessed via product information pages where available).
[2] DailyMed. ULTRAVIST 370 (iopromide injection) prescribing information (if available for US product labeling). https://dailymed.nlm.nih.gov/ (accessed via ULTRAVIST 370 label pages where available).
[3] National Library of Medicine. ClinicalTrials.gov database (search results for ULTRAVIST 370 / iopromide 370, where applicable). https://clinicaltrials.gov/ (accessed via registry search results).
[4] EMA. European public assessment reports and related documentation for iopromide products (where applicable). https://www.ema.europa.eu/ (accessed via relevant product pages).
